Work

Feasibility, Safety, Efficacy And Immunologic Impact Of Daily Ultra-Low-Dose Interleukin-2 For Steroid-Refractory Chronic Graft-Versus-Host Disease: A Phase I Study

Year: 2010

Type: article

Abstract: Regulatory T cells (Treg) are deficient in chronic graft-versus-host-disease (cGVHD). Interleukin-2 (IL-2) is critical in Treg development, expansion and activity. We hypothesized daily subcutaneous (SC) ultra-low-dose IL-2 (8 weeks on, 4 weeks off) may expand Tregs in steroid-refractory cGVHD. We report phase-I IL-2 outcomes at dose-levels: A) 0.3×10^6IU/m2 and B) 1×10^6IU/m2. Dose-level-C accrual is ongoing. Concurrent immunosuppression was allowed.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2009.12.055